CJC-1295 DAC 5 mg – Long-Acting GHRH Analogue

Sale!
CJC-1295 DAC 5 mg – Long-Acting GHRH Analogue

CJC-1295 DAC 5 mg – Long-Acting GHRH Analogue

Original price was: R1 199,99.Current price is: R979,99.

CJC-1295 with DAC (Drug Affinity Complex) is a long-acting analogue of Growth Hormone–Releasing Hormone (GHRH). The DAC modification allows the peptide to bind circulating albumin, significantly extending its half-life compared with short-acting GHRH fragments such as Sermorelin or Modified GRF (1–29).

In controlled research settings, CJC-1295 DAC is used to model sustained GH and IGF-1 elevation, long-term somatotropic axis stimulation, body-composition and visceral adiposity changes, and broader metabolic and protein-turnover pathways. Because of its prolonged activity, CJC-1295 DAC is typically explored with weekly or bi-weekly exposure models rather than daily administration.

Dosage Protocol — Pen System

The Clinic standardizes all cartridges to simplify research use and dose reproducibility.

  • Pen volume: 2 mL
  • Total clicks per pen: 200 clicks
  • CJC-1295 DAC content per cartridge: 5 mg (5,000 mcg)
  • Strength: 5 mg ÷ 200 clicks = 0.025 mg (25 mcg) per click
  • Reference points: 10 clicks = 250 mcg, 20 clicks = 500 mcg, 40 clicks = 1,000 mcg, 60 clicks = 1,500 mcg

This configuration comfortably satisfies The Clinic requirement that mid-range doses utilise at least 10 clicks.

Categories: , , Tags: , , , Brand:

Description

Mechanism of Action
CJC-1295 DAC functions as a GHRH receptor agonist. It binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating endogenous, pulsatile growth hormone (GH) release. The DAC side chain enables a stable association with albumin, which protects the peptide from rapid enzymatic breakdown, extending its activity over several days.This sustained GH stimulation leads to increased IGF-1 levels and influences downstream processes including protein synthesis, lipolysis and tissue-signaling pathways. Research models have explored CJC-1295 DAC in the context of growth, body composition, visceral adiposity and metabolic regulation.

Suggested Dosing (Pen Format – Example Once-Weekly Protocol)

Research Arm / Phase Reference Dose (mcg) Clicks per Injection Example Use-Case (Research Context)
Low-Exposure Arm (Weeks 1–4) 500 mcg 20 clicks Initial GH/IGF-1 response, safety and assay calibration
Standard Arm (Weeks 5–8) 1,000 mcg (1.0 mg) 40 clicks Sustained GH/IGF-1 elevation, body-composition signaling
High-Exposure Arm (Weeks 9–12) 1,500 mcg (1.5 mg) 60 clicks Higher-dose endocrine and metabolic outcome exploration

All values are illustrative research frameworks only and must be aligned with the specific model, ethics approvals and study design. They are not prescribing guidance or human dosing recommendations.

Frequency & Cycle Length

  • Frequency: Typically once-weekly subcutaneous injections in long-acting GHRH models.
  • Alternative designs: Some protocols explore bi-weekly intervals to map decay curves and hormone profiles.
  • Cycle length: GH-axis studies commonly run 8–12 weeks; extended metabolic or body-composition models may run 12–24 weeks.

Product Details & Cartridge Summary

Product Information

  • Compound: CJC-1295 with DAC (long-acting GHRH analogue)
  • Content: 5 mg CJC-1295 DAC per 2 mL cartridge

What’s in the Box

  • 1 × CJC-1295 DAC 5 mg pre-reconstituted in 2 mL bacteriostatic water (Clinic pen compatible)
  • 1 × replacement needle

Expected Outcomes

In controlled settings, CJC-1295 DAC exposure has been associated with:

  • Persistent elevation of GH and IGF-1 after single or repeated weekly doses.
  • Potential improvements or maintenance of lean tissue indices in selected models.
  • Exploratory data on visceral adiposity and metabolic parameters in obesity and lipodystrophy frameworks.

These observations are derived from research and must not be interpreted as therapeutic or guaranteed outcomes.

Related Products

Related products